AU2018338322B2 - A33 antibody compositions and methods of using the same in radioimmunotherapy - Google Patents

A33 antibody compositions and methods of using the same in radioimmunotherapy

Info

Publication number
AU2018338322B2
AU2018338322B2 AU2018338322A AU2018338322A AU2018338322B2 AU 2018338322 B2 AU2018338322 B2 AU 2018338322B2 AU 2018338322 A AU2018338322 A AU 2018338322A AU 2018338322 A AU2018338322 A AU 2018338322A AU 2018338322 B2 AU2018338322 B2 AU 2018338322B2
Authority
AU
Australia
Prior art keywords
antibody
seq
subject
lys
dota
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018338322A
Other languages
English (en)
Other versions
AU2018338322A1 (en
Inventor
Nai-Kong Cheung
Zhihao WU
Hong Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of AU2018338322A1 publication Critical patent/AU2018338322A1/en
Priority to AU2025204844A priority Critical patent/AU2025204844A1/en
Application granted granted Critical
Publication of AU2018338322B2 publication Critical patent/AU2018338322B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2018338322A 2017-09-23 2018-09-21 A33 antibody compositions and methods of using the same in radioimmunotherapy Active AU2018338322B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025204844A AU2025204844A1 (en) 2017-09-23 2025-06-26 A33 antibody compositions and methods of using the same in radioimmunotherapy

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762562373P 2017-09-23 2017-09-23
US201762562374P 2017-09-23 2017-09-23
US62/562,373 2017-09-23
US62/562,374 2017-09-23
PCT/US2018/052253 WO2019060750A2 (en) 2017-09-23 2018-09-21 A33 ANTIBODY COMPOSITIONS AND METHODS OF USE IN RADIOIMMUNOTHERAPY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025204844A Division AU2025204844A1 (en) 2017-09-23 2025-06-26 A33 antibody compositions and methods of using the same in radioimmunotherapy

Publications (2)

Publication Number Publication Date
AU2018338322A1 AU2018338322A1 (en) 2020-04-09
AU2018338322B2 true AU2018338322B2 (en) 2025-07-17

Family

ID=65810903

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018338322A Active AU2018338322B2 (en) 2017-09-23 2018-09-21 A33 antibody compositions and methods of using the same in radioimmunotherapy
AU2025204844A Pending AU2025204844A1 (en) 2017-09-23 2025-06-26 A33 antibody compositions and methods of using the same in radioimmunotherapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025204844A Pending AU2025204844A1 (en) 2017-09-23 2025-06-26 A33 antibody compositions and methods of using the same in radioimmunotherapy

Country Status (9)

Country Link
US (2) US11555072B2 (enExample)
EP (1) EP3684369A4 (enExample)
JP (3) JP7303802B2 (enExample)
KR (1) KR102783937B1 (enExample)
CN (1) CN111372590A (enExample)
AU (2) AU2018338322B2 (enExample)
CA (1) CA3076611A1 (enExample)
IL (1) IL273484B2 (enExample)
WO (1) WO2019060750A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140271462A1 (en) 2013-03-13 2014-09-18 Imaginab, Inc. Antigen binding constructs to cd8
CN115960230A (zh) 2015-08-07 2023-04-14 伊麦吉纳博公司 靶向分子的抗原结合构建体
US11122038B1 (en) * 2017-05-18 2021-09-14 United Services Automobile Association (Usaa) Methods and systems for authentication of new users
EP3898677A1 (en) 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
SG11202106347PA (en) 2018-12-21 2021-07-29 Ose Immunotherapeutics Humanized anti-human-pd-1 antibody
EP3898676A1 (en) 2018-12-21 2021-10-27 OSE Immunotherapeutics Bifunctional anti-pd-1/sirpa molecule
CN113573782B (zh) 2018-12-21 2025-12-16 Ose免疫疗法公司 针对人pd-1的双功能分子
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
US20220177579A1 (en) * 2019-04-08 2022-06-09 Memorial Sloan Kettering Cancer Center Cd19 antibodies and methods of using the same
EP4244242A1 (en) 2020-11-16 2023-09-20 Technische Universität München Bioorthogonal reporter gene system
AU2021381768A1 (en) * 2020-11-18 2023-06-22 Memorial Sloan Kettering Cancer Center Anti-gpa33 multi-specific antibodies and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6307026B1 (en) * 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
US20020062009A1 (en) * 1998-04-28 2002-05-23 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
WO2016054005A1 (en) * 2014-09-30 2016-04-07 The Medical College Of Wisconsin, Inc. Universal platform for targeting therapies to treat neurological diseases
WO2016130539A2 (en) * 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
WO2016164308A1 (en) * 2015-04-06 2016-10-13 Subdomain, Llc De novo binding domain containing polypeptides and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69331735T2 (de) * 1992-12-10 2002-09-26 Celltech Therapeutics Ltd., Slough Gegen das A33 Antigen gerichtete Humanisierte Antikörper
WO2006028197A1 (ja) * 2004-09-06 2006-03-16 Kirin Beer Kabushiki Kaisha 抗a33抗体
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307026B1 (en) * 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
WO1998052976A1 (en) * 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US20020062009A1 (en) * 1998-04-28 2002-05-23 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
WO2016054005A1 (en) * 2014-09-30 2016-04-07 The Medical College Of Wisconsin, Inc. Universal platform for targeting therapies to treat neurological diseases
WO2016130539A2 (en) * 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
WO2016164308A1 (en) * 2015-04-06 2016-10-13 Subdomain, Llc De novo binding domain containing polypeptides and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
King, D. et al., 'Preparation and precinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy', British Journal of Cancer, (1995-12-01), vol. 72, no. 6, pages 1364 - 1372. *

Also Published As

Publication number Publication date
KR20200057759A (ko) 2020-05-26
JP7303802B2 (ja) 2023-07-05
JP2023138957A (ja) 2023-10-03
KR102783937B1 (ko) 2025-03-24
IL273484A (en) 2020-05-31
WO2019060750A3 (en) 2019-05-16
EP3684369A4 (en) 2021-06-23
AU2018338322A1 (en) 2020-04-09
WO2019060750A2 (en) 2019-03-28
US20200291112A1 (en) 2020-09-17
AU2025204844A1 (en) 2025-07-17
CA3076611A1 (en) 2019-03-28
IL273484B2 (en) 2025-12-01
US11555072B2 (en) 2023-01-17
EP3684369A2 (en) 2020-07-29
US20240327511A1 (en) 2024-10-03
CN111372590A (zh) 2020-07-03
JP2025061650A (ja) 2025-04-11
IL273484B1 (en) 2025-08-01
JP2020534017A (ja) 2020-11-26

Similar Documents

Publication Publication Date Title
US20240327511A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
US12486323B2 (en) Anti-L1-CAM antibodies and uses thereof
US12441793B2 (en) CD33 antibodies and methods of using the same to treat cancer
US20220348686A1 (en) Anti-steap1 antibodies and uses thereof
US20230212289A1 (en) Anti-cd3 antibodies and uses thereof
US20220251192A1 (en) Anti-cd33 antibodies for treating cancer
US12195554B2 (en) Anti-polysialic acid antibodies and uses thereof
US20220242967A1 (en) Anti-glypican-3 antibodies and uses thereof
WO2024031009A2 (en) Anti-cd24 antibodies and uses thereof
WO2025064419A1 (en) Gpa33 antibody compositions and uses thereof
EA046795B1 (ru) Композиции на основе антител против a33 и способы их применения в радиоиммунотерапии

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)